Skyway is in constant search for the best ways to treat our clients, meeting them where they are, and offering interventions that support their growth and healing. Where “traditional” medical therapies sometimes fall short, newer interventions are joining the force toward more notable and significant relief.
We are now introducing Spravato (esketamine) administration and integration to the list of therapeutic offerings for current IOP/PHP clients in both our Skokie and in our new Downers Grove locations.
The data tells us that between 15 and 30 percent of depressive episodes fail to respond to adequate trials of two antidepressants, and 68 percent of individuals do not achieve remission from depression after a first-line course of treatment.
This failure to respond may often reflect other factors including biological resistance, diagnostic error, limitations of current therapies, psychosocial variables, history, and so much more. Newer medical interventions, like Spravato, have the unique ability to make the brain more plastic, creating new neuropathways to support a break from stuck patterns, and providing more support for clients seeking relief they haven’t received before.
What Is Spravato?
Spravato is an FDA-approved treatment specifically designed for adults with “treatment-resistant” depression and Major Depressive Disorder with suicidal ideation or behaviors. Administered as a nasal spray under medical supervision, Spravato works differently from traditional antidepressants by targeting specific brain receptors that are responsible for regulating mood.
This innovative approach has created new possibilities for individuals who have tried multiple psychotropic medication trials (typically SSRIs or selective serotonin reuptake inhibitors) and other therapies for depression with little to no improvement.
By offering Spravato to Skyway clients, we can further customize care and enhance our therapeutic work by increasing brain plasticity and the ability to regulate mood without significant (and sometimes permanent) side effects. Improved mood regulation also allows clients greater ability to tolerate trauma treatments and more intensive psychotherapies.
Why is Skyway Behavioral Health Offering Spravato?
Skyway’s mission is to provide personalized and evidence-based care. By adding Spravato to our range of services, we are helping clients explore new ways of finding relief from current symptoms while improving the ability to generalize treatment gains to their home and/or everyday environments.
What Can Clients Expect During Spravato Treatment at Skyway?
The decision to begin Spravato treatment is made collaboratively between clients and their full Skyway team. Like any new therapy, the process begins with a psychiatric evaluation that determines someone’s eligibility for adjunct Spravato treatment. Clients will also be monitored for an extended time period after Spravato administration in order to insure that clients feel safe and supported during their treatment.
What’s Next?
Whether you are a client exploring treatment options or a professional looking to guide your clients to the right care, our team is here to answer your questions and to help you determine if Skyway and our Spravato treatment might be the next step.
For more information, or to schedule a free, 90-minute virtual assessment, call: 224-970-2226 or complete a referral form today. **Please note: Spravato treatment will initially be offered to our current clients, only, who would have to be participating in one of Skyway’s intensive treatment programs to access this care.
